Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 2
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) J…
Adamantinomatous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma
Nationwide Children's HospitalNCT05233397
Phase 2
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biolo…
Adamantinous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma
Nationwide Children's HospitalNCT05286788